PRKN and amyotrophic lateral sclerosis: Finally, we provide updated information on mitochondrial dysfunction in sporadic and major genetic forms TDP-43 proteinopathies and discuss the potential rationale for using parkin as a therapeutic target in ALS–FTSD.